All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment

Dr. Cusin has received speaking and consulting fees from Alkermes, Boehringer Ingelheim, Janssen, and Takeda, and she is named as an inventor on a patent (Acyclic cucurbit[N]uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders). Dr. Sakurai has received manuscript or speakers honoraria from Eli Lilly, Meiji Seika, Mitsubishi Tanabe, Otsuka, Sumitomo Dainippon, and Yoshitomi Yakuhin, and he receives support from the Japanese Society of Clinical Neuropsychopharmacology and the Uehara Memorial Foundation. Dr. Fava has received research support from, has served as an adviser or consultant to, has had speaking or publishing roles for, and/or has equity in Abbott, Acadia, Adamed, Advanced Meeting Partners, Affectis, Alkermes, Amarin, American Cyanamid, the American Society of Clinical Psychopharmacology, APA, Aspect Medical Systems, AstraZeneca, Auspex Pharmaceuticals, Avanir, Axsome, Bayer, Belvoir Media Group, Best Practice Project Management, Biogen, Biohaven, BioMarin, BioResearch, Biovail, BioXcel Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, the Brain and Behavior Research Foundation, BrainCells, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Cerecor, Clarus Funds, Clexio Biosciences, Clintara, the CME Institute, CNS Response, Compellis, Covance, Covidien, Cypress, DiagnoSearch Life Sciences, Dov, Edgemont, Eisai, Eli Lilly, EnVivo, ePharmaSolutions, Epix, Euthymics Bioscience, Fabre-Kramer, Forest, Forum, Ganeden, Genomind, GlaxoSmithKline, Grünenthal, the Harvard Clinical Research Institute, Hoffmann–La Roche, ICON, Imedex, Indivior, Ingenix, Intracellular, Janssen, Jazz, the Jed Foundation, Johnson & Johnson, Knoll, Labopharm, Lichtwer, Lorex, Lundbeck, Marinus, the Massachusetts General Hospital Psychiatry Academy, MedAvante, Merck, MSI Methylation Sciences, the National Alliance for Research on Schizophrenia and Depression, the National Center for Complementary and Alternative Medicine, the National Coordinating Center for Integrative Medicine, Naurex, Navitor, Nestle Health Sciences, Neuralstem, Neuronetics, NeuroRx, NextWave, NIDA, NIMH, Novartis, Nutrition 21, Orexigen, Organon, Osmotica, Otsuka, PamLab, Pfizer, Pharmacia-Upjohn, Pharmaceutical Research Associates, Pharmastar, Pharmavite, PharmoRx Therapeutics, Pharmaceutical Product Development, Photothera, Polaris, Praxis Precision Medicines, Precision Human Biolaboratory, Prexa, PsychoGenics, PsyBrain, Psylin, PThera, Purdue, Puretech Ventures, RCT Logic, Reckitt Benckiser, Relmada, Rexahn, Ridge Diagnostics, Roche, Sanofi-Aventis, Schering-Plough, Sepracor, Servier, Shenox, Shire, Solvay, Somaxon, Somerset, the Stanley Medical Research Institute, Sumitomo Dainippon, Sunovion, Supernus, Synthélabo, Taisho, Takeda, Tal Medical, Tetragenex, Teva, Transcept, TransForm, United BioSource, the Usona Institute, Vanda, Versant, VistaGen, and Wyeth-Ayerst; he is named as an inventor on patents for sequential parallel comparison design, licensed by Massachusetts General Hospital to Pharmaceutical Product Development; he is named as an inventor on patents for the pharmacogenomics of depression treatment with folate; he is named as an inventor on a patent application for a combination of ketamine plus scopolamine in major depressive disorder, licensed by Massachusetts General Hospital to Biohaven; he holds copyright for the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire, the Sexual Functioning Inventory, the Antidepressant Treatment Response Questionnaire, the Discontinuation-Emergent Signs and Symptoms inventory, the Symptoms of Depression Questionnaire, and the SAFER criteria for clinical trials and research; and he has received royalties from Lippincott Williams & Wilkins for the book Natural Medications for Psychiatric Disorders: Considering the Alternatives. Dr. Mischoulon has received research support from Nordic Naturals; he has provided unpaid consulting for Gnosis USA and Pharmavite; he has received speakers honoraria from Blackmores, the Massachusetts General Hospital Psychiatry Academy, and PeerPoint Medical Education Institute; and he has received royalties from Lippincott Williams & Wilkins for the book Natural Medications for Psychiatric Disorders: Considering the Alternatives. Dr. Bentley, Dr. Pedrelli, and Dr. Foster report no financial relationships with commercial interests.